Popular Articles

Genetically Elevated Levels Of Lipoprotein Associated With Increased Risk Of Heart Attack
A genetic analysis of data from three studies suggests that genetically elevated levels of lipoprotein(a) are associated with an increased risk of heart attack, according to a study in the June 10 issue of JAMA.
generic viagra online
Insurance Insiders Give Views On Health Reform
In an interview with the Seattle Post-Intelligencer, Washington state Insurance Commissioner Mike Kreidler called the American health system an out-dated, World War II-era obstacle to economic progress. "We"ve been talking about health-care reform in this country for over 100 years, and its never happened," he said. However, he added, "I believe that Congress will be successful." Kreidler, a Democrat, was a member of Congress in the 1990s, when the Clinton administration attempted an overhaul. This time around, he said, "We"re still in July, and they"re making huge progress" (Pulkkinen, 8/2).
News of the day
Supreme Court Nominees Should Disclose Views On Constitutional Issues, USA Today Opinion Piece States
One thing that "has been conspicuously absent" from the confirmation hearings for Supreme Court nominee Sonia Sotomayor is "substance," Jonathan Turley, the Shapiro Professor of Public Interest Law at George Washington University, writes in a USA Today opinion piece. According to Turley, "The vast majority of questions and answers remained on a shallow and predictable level where Sotomayor did little more than describe current doctrines and case law -- avoiding disclosures of her own views." He continues, "What is most striking is how Sotomayor"s statements were virtually identical to both her conservative and liberal predecessors," including her comments that Roe v. Wade and Planned Parenthood v. Casey are "the precedent of the court."Turley writes, "The content-light character in these hearings is largely the product of the "Ginsburg rule" -- named after Justice Ruth Bader Ginsburg, who refused to answer questions in her 1993 confirmation hearing about any case or matter upon which she might later vote." According to Turley, "Later nominees for both parties have relied on the Ginsburg rule to turn the hearings into prolonged photo-ops for senators, who largely ask wafer-thin questions to solicit largely scripted answers." The rule "allows nominees to get by with meaningless sound bites that promise to respect precedent, the Framers [of the Constitution] and collegiality in general," he adds. Furthermore, it "tells the public nothing about a nominee"s philosophy or purpose before giving her life tenure on the world"s most powerful court," Turley writes.According to Turley, there is a "simple solution to returning substance to the confirmation process: End the Ginsburg rule by insisting that nominees answer questions about their specific views on constitutional rights." Although "the current system works well for presidents, nominees and senators," it "does little for the public or the system of justice," he writes (Turley, USA Today, 7/16).
Medical Devices

Arthritis Drug Shows Promise In Clinical Trial

A clinical trial of masitinib, a drug in development for the treatment of rheumatoid arthritis, has shown it to be well tolerated and effective. Researchers writing in BioMed Central"s open access journal Arthritis Research and Therapy have shown that treatment with masitinib significantly reduced the severity of active arthritis. Olivier Hermine worked with researchers from several French hospitals to carry out this trial in 43 patients with arthritis resistant to current treatments. He said, "In choosing which interventions to use for the management of rheumatoid arthritis, it is important to recognise that treatment should aim to keep the disease in remission and not be used intermittently to manage exacerbations. We are encouraged from this study that masitinib not only appears to be effective, but that within the first 3 months of treatment the worst of its side-effects were over, possibly making it suitable for long-term treatment regimens". He adds, "The results of this study also help establish the critical role of mast cells in the pathogenesis of rheumatoid arthritis and demonstrate their viability as a therapeutic target. There is sufficient compelling evidence to warrant further placebo-controlled investigation". Masitinib inhibits the activity of mast cells, a component of the immune system thought to be involved in the pathogenesis of rheumatoid arthritis. The clinical improvement described in the study was supported by laboratory evidence of reduced inflammation. The authors found that adverse effects of the treatment were mainly mild to moderate. Alain Moussy from AB Science, a pharmaceutical company who are developing masitinib for multiple indications in human and animal medicine said, "This is a milestone article for us, being the first publication of masitinib in a human study". Speaking about the drug, Alain Moussy said, "Our preclinical studies have shown that masitinib selectively targets cell receptors known to be involved in various disease processes but does not affect those associated with toxicity, particularly cardiotoxicity". Notes: Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study Jacques Tebib, Xavier Mariette, Pierre Bourgeois, Renç©-Marc Flipo, Philippe Gaudin, Xavier Le Loç«t, Paul Gineste, Laurent Guy, Colin D Mansfield, Alain Moussy, Patrice Dubreuil, Olivier Hermine and Jean Sibilia http://arthritis-research.com/ Graeme Baldwin BioMed Central


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):